BRAF and melanoma: Our previous studies indicated that CD271 expression within primary melanomas correlates with a more aggressive tumor phenotype and reduced patient survival [12], with other studies suggesting that CD271 expression is induced during acquired resistance to BRAF inhibition [13,14,15].